Estelle Fruchet, General Manager of Shionogi Europe for France, emphasizes the urgent need for new antibiotics due to rising antimicrobial resistance (AMR), which is causing significant health and economic crises. AMR leads to over 35,000 deaths annually in the EU and 1.3 million globally, with projected costs of $412 billion per year in healthcare and lost productivity. The pharmaceutical industry struggles to develop new antibiotics due to low market prices and high failure rates. Innovative financing models, like the UK's subscription approach, are suggested to encourage development. Collaboration among various sectors is crucial to combat AMR effectively.